VPS53-Related Pontocerebellar Hypoplasia Type 2E

Mendelian MONDO:0014370 Pathograph 13 Show in embeddings browser Pontocerebellar Hypoplasia Neurodevelopmental Disorder

VPS53-related pontocerebellar hypoplasia type 2E is an autosomal recessive GARP-complex vesicular-trafficking disorder caused by biallelic VPS53 variants. VPS53 deficiency impairs endosome-to-Golgi retrograde recycling, causing abnormal CD63-positive endosomal or vesicular bodies in patient fibroblasts. Cellular studies also demonstrate disrupted sphingolipid homeostasis, lysosomal function, and Golgi glycoprotein processing. The clinical syndrome overlaps historical progressive cerebello-cerebral atrophy type 2 and includes severe neurodevelopmental impairment, progressive microcephaly, epilepsy, spasticity, pontocerebellar/cerebello-cerebral atrophy, and occasional hepatic or hearing involvement.

Ask OpenScientist

Ask a research question about VPS53-Related Pontocerebellar Hypoplasia Type 2E. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
5
Pathophys.
7
Phenotypes
1
Gaps
13
Pathograph
1
Genes
1
Medical Actions
2
Models
1
Deep Research
🏷

Classifications

ICIMD (Inherited Metabolic Disorders)
vesicular trafficking
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
VPS53-related PCH2E/PCCA2 is reported with biallelic VPS53 founder variants and autosomal recessive segregation.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"compound heterozygous mutations in VPS53, segregating as expected for autosomal recessive heredity within all four families"
The discovery report directly supports autosomal recessive VPS53 disease.
?

Discussions and Knowledge Gaps

1
Which VPS53-dependent lipid, lysosomal, or glycosylation abnormalities drive the human neurologic phenotype, and do the cellular rescue findings translate to disease-relevant neural models?
HUMAN MODEL MISMATCH OPEN gap_vps53_cellular_mechanisms_to_human_phenotype
Attached to
pathophysiology#Sphingolipid and lysosomal homeostasis disruption pathophysiology#GARP-dependent Golgi enzyme mislocalization and glycosylation defects
Patient fibroblasts and engineered human cell lines establish cellular abnormalities, but the retained evidence does not establish that either the lipid/lysosomal or glycosylation branch mediates the neurologic, hepatic, or hearing manifestations.
Proposed experiments
Isogenic rescue in patient-derived neural models
exp_vps53_neural_rescue
Derive patient iPSC neurons and cerebellar organoids and test whether VPS53 correction rescues trafficking, lipid, and glycosylation defects.
Sphingolipid-pathway perturbation in VPS53 neural models
exp_vps53_sphingolipid_perturbation
Perturb sphingolipid synthesis in disease-relevant neural models and measure neuronal survival and network phenotypes.
Show evidence (1 reference)
PMID:34161137 SUPPORT In Vitro
"Our findings may be relevant to the pathogenesis of GARP-deficiency syndrome in humans"
The authors explicitly frame the human-disease relevance as potential, underscoring the translational gap.
⚙

Pathophysiology

5
VPS53 GARP-complex retrograde-trafficking defect
Biallelic VPS53 variants disrupt the GARP complex, impairing retrograde recycling of endocytic vesicles to the Golgi.
VPS53 hgnc:25608 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves VPS53 (hgnc:25608). hgnc:25608 is a gene from the HUGO Gene Nomenclature Committee.
retrograde transport, endosome to Golgi GO:0042147 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased retrograde transport, endosome to Golgi (GO:0042147). GO:0042147 is a biological process from the Gene Ontology. ↓ DECREASED Golgi vesicle transport GO:0048193 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Golgi vesicle transport (GO:0048193). GO:0048193 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Golgi apparatus GO:0005794 Gene Ontology (GO) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in Golgi apparatus (GO:0005794). GO:0005794 is an anatomical location from the Gene Ontology.
Downstream
Abnormal endosomal vesicular bodies GARP dysfunction produces abnormal endosomal or vesicular-body morphology in patient fibroblasts.
Sphingolipid and lysosomal homeostasis disruption Experimental GARP deficiency disrupts sphingolipid balance and lysosomal function; patient fibroblasts reproduce the lipid abnormalities.
GARP-dependent Golgi enzyme mislocalization and glycosylation defects VPS53 knockout disrupts Golgi-enzyme retention and N- and O-glycan processing in human cells.
Progressive cerebello-cerebral atrophy Biallelic VPS53 variants cause PCCA2, but the intervening route from GARP trafficking dysfunction to progressive brain atrophy is not established.
Show evidence (2 references)
PMID:24577744 SUPPORT Human Clinical
"Autosomal recessive PCCA type 2 is caused by VPS53 mutations."
The discovery report establishes VPS53 as the causal disease gene.
PMID:24577744 SUPPORT Other
"The Golgi-associated retrograde protein (GARP) complex is involved in the retrograde pathway recycling endocytic vesicles to Golgi"
This defines the primary vesicular-trafficking process disrupted by VPS53 disease.
Abnormal endosomal vesicular bodies
Patient fibroblasts show swollen and abnormally numerous CD63-positive vesicular bodies consistent with disrupted intermediate recycling or late endosomal trafficking downstream of VPS53/GARP dysfunction.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
endosome organization GO:0007032 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal endosome organization (GO:0007032). GO:0007032 is a biological process from the Gene Ontology. ⚠ ABNORMAL retrograde transport, endosome to Golgi GO:0042147 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased retrograde transport, endosome to Golgi (GO:0042147). GO:0042147 is a biological process from the Gene Ontology. ↓ DECREASED
Experimental models
PCCA2 patient-fibroblast trafficking and lipid model PRIMARY CELL CULTURE Patient-cell microscopy measures the endosomal morphology defect.
Show evidence (1 reference)
PMID:24577744 SUPPORT In Vitro
"Immunofluorescent microscopy demonstrated swollen and abnormally numerous CD63 positive vesicular bodies, likely intermediate recycling/late endosomes, in fibroblasts of affected individuals."
Patient fibroblast microscopy directly supports abnormal endosomal vesicular bodies.
Sphingolipid and lysosomal homeostasis disruption
GARP deficiency reroutes or misbalances sphingolipid trafficking, causing accumulation of sphingolipid intermediates and lysosomal dysfunction in model systems and PCCA2 patient fibroblasts.
fibroblast CL:0000057 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves fibroblast (CL:0000057). CL:0000057 is a cell type from the Cell Ontology.
lysosome organization GO:0007040 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal lysosome organization (GO:0007040). GO:0007040 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
PCCA2 patient-fibroblast trafficking and lipid model PRIMARY CELL CULTURE Patient-cell lipidomics measures the sphingolipid imbalance.
Show evidence (2 references)
PMID:26357016 SUPPORT In Vitro
"GARP deficiency leads to accumulation of sphingolipid synthesis intermediates, changes in sterol distribution, and lysosomal dysfunction."
The GARP lipid-homeostasis study defines the downstream sphingolipid and lysosomal defect.
PMID:26357016 SUPPORT In Vitro
"PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and ceramides compared with control fibroblasts."
Patient fibroblast lipidomics supports accumulation of sphingolipid intermediates in VPS53-related disease.
GARP-dependent Golgi enzyme mislocalization and glycosylation defects
VPS53-containing GARP activity is required to retain Golgi glycosylation enzymes. VPS53 knockout causes abnormal processing of N-linked and O-linked glycoproteins in human cell lines; its contribution to the human neurologic phenotype remains unresolved.
protein N-linked glycosylation GO:0006487 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal protein N-linked glycosylation (GO:0006487). GO:0006487 is a biological process from the Gene Ontology. ⚠ ABNORMAL protein O-linked glycosylation GO:0006493 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal protein O-linked glycosylation (GO:0006493). GO:0006493 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Experimental models
VPS53-knockout RPE1 glycosylation model CELL LINE VPS53 knockout tests the GARP-dependent glycosylation branch.
Show evidence (1 reference)
PMID:34161137 SUPPORT In Vitro
"KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects in plasma membrane, intracellular, and secreted glycoproteins."
VPS53 knockout human-cell experiments support defective Golgi N- and O-glycosylation downstream of GARP dysfunction.
Progressive cerebello-cerebral atrophy
Progressive cerebellar and cerebral atrophy defines the original PCCA2 presentation. The discovery cohort linked this structural brain disorder to profound intellectual impairment, progressive microcephaly, spasticity, and early-onset epilepsy.
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology. cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cerebellar atrophy Cerebellar atrophy is a structural component of the observed PCCA presentation.
Microcephaly Progressive microcephaly accompanies the PCCA2 neurodegenerative course.
Spasticity Spasticity is part of the PCCA2 neurologic progression.
Seizures Early-onset epilepsy is part of the PCCA2 neurologic progression.
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental retardation, progressive microcephaly, spasticity and early onset epilepsy"
Directly defines the progressive structural brain presentation and associated features.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for VPS53-Related Pontocerebellar Hypoplasia Type 2E Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

7
Ear 1
Hearing impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39842660 SUPPORT Human Clinical
"classic phenotypic features along with liver disease and deafness"
Deafness maps to the HPO hearing impairment term.
Musculoskeletal 1
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"progressive microcephaly, spasticity and early onset epilepsy"
The discovery report explicitly includes spasticity.
Nervous System 3
Cerebellar atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272), qualified as course progressive. HP:0001272 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental retardation, progressive microcephaly, spasticity and early onset epilepsy"
Supports progressive cerebellar atrophy rather than congenital cerebellar hypoplasia.
Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"spasticity and early onset epilepsy"
The discovery report explicitly includes early-onset epilepsy.
Global developmental delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39842660 SUPPORT Human Clinical
"microcephaly, severe neurodevelopmental impairment and epilepsy."
The report supports severe neurodevelopmental impairment.
Other 2
Microcephaly Progressive microcephaly HP:0000253 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive microcephaly (HP:0000253). HP:0000253 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"progressive microcephaly, spasticity and early onset epilepsy"
The discovery report explicitly includes progressive microcephaly.
Abnormality of the liver HP:0001392 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormality of the liver (HP:0001392). HP:0001392 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:39842660 SUPPORT Human Clinical
"classic phenotypic features along with liver disease and deafness"
A 2025 case report explicitly adds liver disease to the VPS53-related PCH2E phenotype; the generic HPO liver abnormality term is used because the cached abstract does not specify a narrower hepatic diagnosis.
🧬

Genetic Associations

1
VPS53 biallelic pathogenic variants (Biallelic pathogenic variants)
Gene: VPS53 hgnc:25608 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is VPS53 (hgnc:25608). hgnc:25608 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:24577744 SUPPORT Human Clinical
"Whole exome sequencing identified only two mutations within this locus, which were common to the affected individuals: compound heterozygous mutations in VPS53"
Exome sequencing identified biallelic VPS53 variants shared by affected individuals.
🗃️

External Assertions

1
OMIM pontocerebellar hypoplasia type 2E record
OMIM disease record OMIM:615851
OMIM phenotype identifier for VPS53-related pontocerebellar hypoplasia type 2E / progressive cerebello-cerebral atrophy type 2.
💊

Medical Actions

1
Sphingolipid-synthesis inhibition (preclinical)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Inhibition of the first step of de novo sphingolipid synthesis mitigated cellular phenotypes in GARP-deficient yeast and mammalian cells. This is a preclinical mechanistic strategy, not an established treatment for PCH2E.
Mechanism Target:
INHIBITS Sphingolipid and lysosomal homeostasis disruption — Reducing de novo sphingolipid synthesis aims to limit toxic intermediate accumulation.
Show evidence (1 reference)
PMID:26357016 SUPPORT In Vitro
"Inhibition of the first step of de novo sphingolipid synthesis is sufficient to mitigate many of the phenotypes of GARP-deficient yeast or mammalian cells."
Supports a preclinical cellular strategy only; no human efficacy is claimed.
🧫

Experimental Models

2
PCCA2 patient-fibroblast trafficking and lipid model PRIMARY_CELL_CULTURE
Patient fibroblasts reproduce abnormal CD63-positive vesicular bodies and sphingolipid-intermediate accumulation associated with VPS53-related PCCA2.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
Fibroblasts from individuals with VPS53-related PCCA2
Pathograph links
Abnormal endosomal vesicular bodies Patient-cell microscopy measures the endosomal morphology defect.
Show evidence (1 reference)
PMID:24577744 SUPPORT In Vitro
"Immunofluorescent microscopy demonstrated swollen and abnormally numerous CD63 positive vesicular bodies, likely intermediate recycling/late endosomes, in fibroblasts of affected individuals."
The model directly reproduces the endosomal phenotype.
Sphingolipid and lysosomal homeostasis disruption Patient-cell lipidomics measures the sphingolipid imbalance.
Show evidence (1 reference)
PMID:26357016 SUPPORT In Vitro
"PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and ceramides compared with control fibroblasts."
Patient fibroblasts directly show the modeled lipid imbalance.
Findings
PCCA2 fibroblasts accumulate sphingolipid intermediates.
"PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and ceramides compared with control fibroblasts."
Show evidence (1 reference)
PMID:26357016 SUPPORT In Vitro
"PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and ceramides compared with control fibroblasts."
The finding is measured directly in affected-person cells.
Show evidence (1 reference)
PMID:24577744 SUPPORT In Vitro
"Immunofluorescent microscopy demonstrated swollen and abnormally numerous CD63 positive vesicular bodies, likely intermediate recycling/late endosomes, in fibroblasts of affected individuals."
Establishes affected-person fibroblasts as a cellular model.
VPS53-knockout RPE1 glycosylation model CELL_LINE
VPS53 knockout and gene rescue test the requirement for GARP in Golgi-enzyme retention and N- and O-glycan processing.
Organism
human NCBITaxon:9606 NCBI Taxonomy (NCBITaxon) Relation: this experimental model is built in this organism This experimental model is built in human, annotated with Homo sapiens (NCBITaxon:9606). NCBITaxon:9606 is an organism from the NCBI Taxonomy.
Cell source
CRISPR VPS53-knockout human RPE1 cells with VPS53 rescue clones
Pathograph links
GARP-dependent Golgi enzyme mislocalization and glycosylation defects VPS53 knockout tests the GARP-dependent glycosylation branch.
Show evidence (1 reference)
PMID:34161137 SUPPORT In Vitro
"KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects in plasma membrane, intracellular, and secreted glycoproteins."
The knockout directly reproduces the modeled defect.
Findings
VPS53 rescue reverses the glycosylation defects in knockout cells.
"These glycosylation defects could also be rescued by stable expression of the corresponding genes in the KO cells"
Show evidence (1 reference)
PMID:34161137 SUPPORT In Vitro
"These glycosylation defects could also be rescued by stable expression of the corresponding genes in the KO cells"
Genetic rescue supports VPS53 dependence of the cellular phenotype.
Show evidence (1 reference)
PMID:34161137 SUPPORT In Vitro
"KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects in plasma membrane, intracellular, and secreted glycoproteins."
Establishes the human-cell knockout model and its readout.
{ }

Source YAML

click to show 
name: VPS53-Related Pontocerebellar Hypoplasia Type 2E
creation_date: "2026-07-06T12:00:00Z"
category: Mendelian
description: >-
  VPS53-related pontocerebellar hypoplasia type 2E is an autosomal recessive
  GARP-complex vesicular-trafficking disorder caused by biallelic VPS53
  variants. VPS53 deficiency impairs endosome-to-Golgi retrograde recycling,
  causing abnormal CD63-positive endosomal or vesicular bodies in patient
  fibroblasts. Cellular studies also demonstrate disrupted sphingolipid
  homeostasis, lysosomal function, and Golgi glycoprotein processing. The
  clinical syndrome overlaps
  historical progressive cerebello-cerebral atrophy type 2 and includes severe
  neurodevelopmental impairment, progressive microcephaly, epilepsy, spasticity,
  pontocerebellar/cerebello-cerebral atrophy, and occasional hepatic or hearing
  involvement.
disease_term:
  preferred_term: pontocerebellar hypoplasia type 2E
  term:
    id: MONDO:0014370
    label: pontocerebellar hypoplasia type 2E
parents:
- Pontocerebellar Hypoplasia
- Neurodevelopmental Disorder
synonyms:
- VPS53-related PCH2E
- pontocerebellar hypoplasia type 2E
- PCH2E
- progressive cerebello-cerebral atrophy type 2
- PCCA2
- VPS53 deficiency
notes: >-
  The local PCH2 candidate was audited and not edited: that entry models the
  TSEN54/TSEN-complex PCH2 mechanism, while this MONDO:0014370 disease is a
  distinct VPS53/GARP-complex retrograde-trafficking disorder. VPS53-related
  disease is therefore curated as its own disorder entry with vesicular
  trafficking as the primary ICIMD placement and glycosylation as a downstream
  Golgi-machinery consequence.
external_assertions:
- name: OMIM pontocerebellar hypoplasia type 2E record
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:615851
  description: >-
    OMIM phenotype identifier for VPS53-related pontocerebellar hypoplasia type
    2E / progressive cerebello-cerebral atrophy type 2.
classifications:
  icimd_category:
  - classification_value: vesicular_trafficking
    notes: >-
      WP-068 classification 19.6.68.01: Complex Molecule and Organelle
      Metabolism, disorders of organelle biogenesis, dynamics and interactions,
      disorders of vesicular trafficking.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    VPS53-related PCH2E/PCCA2 is reported with biallelic VPS53 founder variants
    and autosomal recessive segregation.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      compound heterozygous mutations in VPS53, segregating as expected for
      autosomal recessive heredity within all four families
    explanation: >-
      The discovery report directly supports autosomal recessive VPS53 disease.
pathophysiology:
- name: VPS53 GARP-complex retrograde-trafficking defect
  biological_scale: CELLULAR
  description: >-
    Biallelic VPS53 variants disrupt the GARP complex, impairing retrograde
    recycling of endocytic vesicles to the Golgi.
  genes:
  - preferred_term: VPS53
    term:
      id: hgnc:25608
      label: VPS53
  biological_processes:
  - preferred_term: retrograde transport, endosome to Golgi
    modifier: DECREASED
    term:
      id: GO:0042147
      label: retrograde transport, endosome to Golgi
  - preferred_term: Golgi vesicle transport
    modifier: ABNORMAL
    term:
      id: GO:0048193
      label: Golgi vesicle transport
  locations:
  - preferred_term: Golgi apparatus
    term:
      id: GO:0005794
      label: Golgi apparatus
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal recessive PCCA type 2 is caused by VPS53 mutations."
    explanation: >-
      The discovery report establishes VPS53 as the causal disease gene.
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The Golgi-associated retrograde protein (GARP) complex is involved in the
      retrograde pathway recycling endocytic vesicles to Golgi
    explanation: >-
      This defines the primary vesicular-trafficking process disrupted by VPS53
      disease.
  downstream:
  - target: Abnormal endosomal vesicular bodies
    causal_link_type: DIRECT
    description: >-
      GARP dysfunction produces abnormal endosomal or vesicular-body morphology
      in patient fibroblasts.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Immunofluorescent microscopy demonstrated swollen and abnormally
        numerous CD63 positive vesicular bodies, likely intermediate
        recycling/late endosomes, in fibroblasts of affected individuals.
      explanation: >-
        Patient fibroblast microscopy directly supports abnormal endosomal
        vesicular bodies.
  - target: Sphingolipid and lysosomal homeostasis disruption
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired GARP-mediated endosome-to-Golgi retrograde recycling
    description: >-
      Experimental GARP deficiency disrupts sphingolipid balance and lysosomal
      function; patient fibroblasts reproduce the lipid abnormalities.
    evidence:
    - reference: PMID:26357016
      reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        GARP deficiency leads to accumulation of sphingolipid synthesis
        intermediates, changes in sterol distribution, and lysosomal dysfunction.
      explanation: >-
        GARP loss experimentally produces the lipid and lysosomal branch.
    - reference: PMID:26357016
      reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and
        ceramides compared with control fibroblasts.
      explanation: >-
        Affected-person fibroblasts reproduce the sphingolipid abnormality.
  - target: GARP-dependent Golgi enzyme mislocalization and glycosylation defects
    causal_link_type: DIRECT
    description: >-
      VPS53 knockout disrupts Golgi-enzyme retention and N- and O-glycan
      processing in human cells.
    evidence:
    - reference: PMID:34161137
      reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects
        in plasma membrane, intracellular, and secreted glycoproteins.
      explanation: >-
        VPS53 knockout directly supports this GARP-dependent cellular branch.
  - target: Progressive cerebello-cerebral atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Biallelic VPS53 variants cause PCCA2, but the intervening route from GARP
      trafficking dysfunction to progressive brain atrophy is not established.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Autosomal recessive PCCA type 2 is caused by VPS53 mutations."
      explanation: Establishes the causal gene-to-PCCA2 relation while leaving intermediates unknown.
- name: Abnormal endosomal vesicular bodies
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts show swollen and abnormally numerous CD63-positive
    vesicular bodies consistent with disrupted intermediate recycling or late
    endosomal trafficking downstream of VPS53/GARP dysfunction.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: endosome organization
    modifier: ABNORMAL
    term:
      id: GO:0007032
      label: endosome organization
  - preferred_term: retrograde transport, endosome to Golgi
    modifier: DECREASED
    term:
      id: GO:0042147
      label: retrograde transport, endosome to Golgi
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Immunofluorescent microscopy demonstrated swollen and abnormally numerous
      CD63 positive vesicular bodies, likely intermediate recycling/late
      endosomes, in fibroblasts of affected individuals.
    explanation: >-
      Patient fibroblast microscopy directly supports abnormal endosomal
      vesicular bodies.
- name: Sphingolipid and lysosomal homeostasis disruption
  biological_scale: CELLULAR
  description: >-
    GARP deficiency reroutes or misbalances sphingolipid trafficking, causing
    accumulation of sphingolipid intermediates and lysosomal dysfunction in
    model systems and PCCA2 patient fibroblasts.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  chemical_entities:
  - preferred_term: sphingomyelin
    modifier: ABNORMAL
    term:
      id: CHEBI:64583
      label: sphingomyelin
  biological_processes:
  - preferred_term: lysosome organization
    modifier: ABNORMAL
    term:
      id: GO:0007040
      label: lysosome organization
  evidence:
  - reference: PMID:26357016
    reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      GARP deficiency leads to accumulation of sphingolipid synthesis
      intermediates, changes in sterol distribution, and lysosomal dysfunction.
    explanation: >-
      The GARP lipid-homeostasis study defines the downstream sphingolipid and
      lysosomal defect.
  - reference: PMID:26357016
    reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and
      ceramides compared with control fibroblasts.
    explanation: >-
      Patient fibroblast lipidomics supports accumulation of sphingolipid
      intermediates in VPS53-related disease.
- name: GARP-dependent Golgi enzyme mislocalization and glycosylation defects
  biological_scale: CELLULAR
  conforms_to: "congenital_disorder_of_glycosylation#Golgi N-Glycan Processing and Trafficking Defect"
  description: >-
    VPS53-containing GARP activity is required to retain Golgi glycosylation
    enzymes. VPS53 knockout causes abnormal processing of N-linked and O-linked
    glycoproteins in human cell lines; its contribution to the human neurologic
    phenotype remains unresolved.
  biological_processes:
  - preferred_term: protein N-linked glycosylation
    modifier: ABNORMAL
    term:
      id: GO:0006487
      label: protein N-linked glycosylation
  - preferred_term: protein O-linked glycosylation
    modifier: ABNORMAL
    term:
      id: GO:0006493
      label: protein O-linked glycosylation
  chemical_entities:
  - preferred_term: N-glycan
    modifier: ABNORMAL
    term:
      id: CHEBI:59520
      label: N-glycan
  - preferred_term: O-glycan
    modifier: ABNORMAL
    term:
      id: CHEBI:59521
      label: O-glycan
  evidence:
  - reference: PMID:34161137
    reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects
      in plasma membrane, intracellular, and secreted glycoproteins.
    explanation: >-
      VPS53 knockout human-cell experiments support defective Golgi N- and
      O-glycosylation downstream of GARP dysfunction.
- name: Progressive cerebello-cerebral atrophy
  biological_scale: TISSUE
  description: >-
    Progressive cerebellar and cerebral atrophy defines the original PCCA2
    presentation. The discovery cohort linked this structural brain disorder to
    profound intellectual impairment, progressive microcephaly, spasticity, and
    early-onset epilepsy.
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
      retardation, progressive microcephaly, spasticity and early onset epilepsy
    explanation: Directly defines the progressive structural brain presentation and associated features.
  downstream:
  - target: Cerebellar atrophy
    causal_link_type: DIRECT
    description: Cerebellar atrophy is a structural component of the observed PCCA presentation.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
        retardation, progressive microcephaly, spasticity and early onset epilepsy
      explanation: The discovery cohort explicitly observed progressive cerebello-cerebral atrophy.
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Progressive microcephaly accompanies the PCCA2 neurodegenerative course.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
        retardation, progressive microcephaly, spasticity and early onset epilepsy
      explanation: The source explicitly describes PCCA leading to progressive microcephaly.
  - target: Spasticity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Spasticity is part of the PCCA2 neurologic progression.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
        retardation, progressive microcephaly, spasticity and early onset epilepsy
      explanation: The source explicitly describes PCCA leading to spasticity.
  - target: Seizures
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Early-onset epilepsy is part of the PCCA2 neurologic progression.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
        retardation, progressive microcephaly, spasticity and early onset epilepsy
      explanation: The source explicitly describes PCCA leading to early-onset epilepsy.
phenotypes:
- category: Neurological
  name: Cerebellar atrophy
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
    clinical_course: PROGRESSIVE
  description: >-
    Progressive cerebellar involvement is part of the observed
    cerebello-cerebral atrophy presentation.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Progressive cerebello-cerebral atrophy (PCCA) leading to profound mental
      retardation, progressive microcephaly, spasticity and early onset epilepsy
    explanation: Supports progressive cerebellar atrophy rather than congenital cerebellar hypoplasia.
- category: Neurological
  name: Microcephaly
  phenotype_term:
    preferred_term: Progressive microcephaly
    term:
      id: HP:0000253
      label: Progressive microcephaly
  description: >-
    Progressive microcephaly is part of the historical PCCA2 presentation.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive microcephaly, spasticity and early onset epilepsy"
    explanation: >-
      The discovery report explicitly includes progressive microcephaly.
- category: Neurological
  name: Seizures
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  description: >-
    Early-onset epilepsy is a core VPS53-related PCH2E feature.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "spasticity and early onset epilepsy"
    explanation: >-
      The discovery report explicitly includes early-onset epilepsy.
- category: Neurological
  name: Global developmental delay
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  description: >-
    Severe neurodevelopmental impairment is reported in VPS53-related PCH2E.
  evidence:
  - reference: PMID:39842660
    reference_title: "Hepatic manifestations in VPS53-related pontocerebellar hypoplasia type 2E: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "microcephaly, severe neurodevelopmental impairment and epilepsy."
    explanation: >-
      The report supports severe neurodevelopmental impairment.
- category: Neurological
  name: Spasticity
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  description: >-
    Spasticity is part of the historical progressive cerebello-cerebral atrophy
    type 2 presentation.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "progressive microcephaly, spasticity and early onset epilepsy"
    explanation: >-
      The discovery report explicitly includes spasticity.
- category: Hepatic
  name: Abnormality of the liver
  phenotype_term:
    preferred_term: Abnormality of the liver
    term:
      id: HP:0001392
      label: Abnormality of the liver
  description: >-
    Liver disease was reported as an extension feature in one VPS53-related
    PCH2E case.
  evidence:
  - reference: PMID:39842660
    reference_title: "Hepatic manifestations in VPS53-related pontocerebellar hypoplasia type 2E: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "classic phenotypic features along with liver disease and deafness"
    explanation: >-
      A 2025 case report explicitly adds liver disease to the VPS53-related
      PCH2E phenotype; the generic HPO liver abnormality term is used because
      the cached abstract does not specify a narrower hepatic diagnosis.
- category: Hearing
  name: Hearing impairment
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  description: >-
    Deafness was reported as an extension feature in one VPS53-related PCH2E
    case.
  evidence:
  - reference: PMID:39842660
    reference_title: "Hepatic manifestations in VPS53-related pontocerebellar hypoplasia type 2E: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "classic phenotypic features along with liver disease and deafness"
    explanation: >-
      Deafness maps to the HPO hearing impairment term.
genetic:
- name: VPS53 biallelic pathogenic variants
  association: Biallelic pathogenic variants
  relationship_type: CAUSATIVE
  presence: Pathogenic
  gene_term:
    preferred_term: VPS53
    term:
      id: hgnc:25608
      label: VPS53
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
  features: >-
    Reported pathogenic alleles include VPS53 founder variants affecting the
    C-terminal region needed for GARP-complex function.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Whole exome sequencing identified only two mutations within this locus,
      which were common to the affected individuals: compound heterozygous
      mutations in VPS53
    explanation: >-
      Exome sequencing identified biallelic VPS53 variants shared by affected
      individuals.
experimental_models:
- name: PCCA2 patient-fibroblast trafficking and lipid model
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: Fibroblasts from individuals with VPS53-related PCCA2
  description: >-
    Patient fibroblasts reproduce abnormal CD63-positive vesicular bodies and
    sphingolipid-intermediate accumulation associated with VPS53-related PCCA2.
  modeled_mechanisms:
  - target: Abnormal endosomal vesicular bodies
    description: Patient-cell microscopy measures the endosomal morphology defect.
    evidence:
    - reference: PMID:24577744
      reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Immunofluorescent microscopy demonstrated swollen and abnormally
        numerous CD63 positive vesicular bodies, likely intermediate
        recycling/late endosomes, in fibroblasts of affected individuals.
      explanation: The model directly reproduces the endosomal phenotype.
  - target: Sphingolipid and lysosomal homeostasis disruption
    description: Patient-cell lipidomics measures the sphingolipid imbalance.
    evidence:
    - reference: PMID:26357016
      reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and
        ceramides compared with control fibroblasts.
      explanation: Patient fibroblasts directly show the modeled lipid imbalance.
  findings:
  - statement: PCCA2 fibroblasts accumulate sphingolipid intermediates.
    supporting_text: >-
      PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and
      ceramides compared with control fibroblasts.
    evidence:
    - reference: PMID:26357016
      reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        PCCA2 fibroblasts exhibited increases in sphingosine, sphinganine, and
        ceramides compared with control fibroblasts.
      explanation: The finding is measured directly in affected-person cells.
  evidence:
  - reference: PMID:24577744
    reference_title: "VPS53 mutations cause progressive cerebello-cerebral atrophy type 2 (PCCA2)."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Immunofluorescent microscopy demonstrated swollen and abnormally numerous
      CD63 positive vesicular bodies, likely intermediate recycling/late
      endosomes, in fibroblasts of affected individuals.
    explanation: Establishes affected-person fibroblasts as a cellular model.
- name: VPS53-knockout RPE1 glycosylation model
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_source: CRISPR VPS53-knockout human RPE1 cells with VPS53 rescue clones
  description: >-
    VPS53 knockout and gene rescue test the requirement for GARP in Golgi-enzyme
    retention and N- and O-glycan processing.
  modeled_mechanisms:
  - target: GARP-dependent Golgi enzyme mislocalization and glycosylation defects
    description: VPS53 knockout tests the GARP-dependent glycosylation branch.
    evidence:
    - reference: PMID:34161137
      reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects
        in plasma membrane, intracellular, and secreted glycoproteins.
      explanation: The knockout directly reproduces the modeled defect.
  findings:
  - statement: VPS53 rescue reverses the glycosylation defects in knockout cells.
    supporting_text: >-
      These glycosylation defects could also be rescued by stable expression of
      the corresponding genes in the KO cells
    evidence:
    - reference: PMID:34161137
      reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        These glycosylation defects could also be rescued by stable expression
        of the corresponding genes in the KO cells
      explanation: Genetic rescue supports VPS53 dependence of the cellular phenotype.
  evidence:
  - reference: PMID:34161137
    reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      KO of VPS53 or VPS54 in RPE1 cells caused N- and O-glycosylation defects
      in plasma membrane, intracellular, and secreted glycoproteins.
    explanation: Establishes the human-cell knockout model and its readout.
treatments:
- name: Sphingolipid-synthesis inhibition (preclinical)
  description: >-
    Inhibition of the first step of de novo sphingolipid synthesis mitigated
    cellular phenotypes in GARP-deficient yeast and mammalian cells. This is a
    preclinical mechanistic strategy, not an established treatment for PCH2E.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  target_mechanisms:
  - target: Sphingolipid and lysosomal homeostasis disruption
    treatment_effect: INHIBITS
    description: Reducing de novo sphingolipid synthesis aims to limit toxic intermediate accumulation.
  evidence:
  - reference: PMID:26357016
    reference_title: "The GARP complex is required for cellular sphingolipid homeostasis."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Inhibition of the first step of de novo sphingolipid synthesis is
      sufficient to mitigate many of the phenotypes of GARP-deficient yeast or
      mammalian cells.
    explanation: >-
      Supports a preclinical cellular strategy only; no human efficacy is claimed.
discussions:
- discussion_id: gap_vps53_cellular_mechanisms_to_human_phenotype
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Which VPS53-dependent lipid, lysosomal, or glycosylation abnormalities drive
    the human neurologic phenotype, and do the cellular rescue findings translate
    to disease-relevant neural models?
  attaches_to:
  - pathophysiology#Sphingolipid and lysosomal homeostasis disruption
  - pathophysiology#GARP-dependent Golgi enzyme mislocalization and glycosylation defects
  rationale: >-
    Patient fibroblasts and engineered human cell lines establish cellular
    abnormalities, but the retained evidence does not establish that either the
    lipid/lysosomal or glycosylation branch mediates the neurologic, hepatic, or
    hearing manifestations.
  proposed_experiments:
  - experiment_id: exp_vps53_neural_rescue
    name: Isogenic rescue in patient-derived neural models
    description: >-
      Derive patient iPSC neurons and cerebellar organoids and test whether VPS53
      correction rescues trafficking, lipid, and glycosylation defects.
  - experiment_id: exp_vps53_sphingolipid_perturbation
    name: Sphingolipid-pathway perturbation in VPS53 neural models
    description: >-
      Perturb sphingolipid synthesis in disease-relevant neural models and
      measure neuronal survival and network phenotypes.
  evidence:
  - reference: PMID:34161137
    reference_title: "The Golgi-associated retrograde protein (GARP) complex plays an essential role in the maintenance of the Golgi glycosylation machinery."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Our findings may be relevant to the pathogenesis of GARP-deficiency
      syndrome in humans
    explanation: >-
      The authors explicitly frame the human-disease relevance as potential,
      underscoring the translational gap.
review_notes: >-
  The 2026 review separates demonstrated cellular mechanisms from clinical
  association. The pathograph retains three evidence-backed branches from
  VPS53/GARP trafficking dysfunction: abnormal patient-fibroblast endosomes,
  sphingolipid/lysosomal disruption, and Golgi-enzyme/glycosylation defects.
  It does not draw causal arrows from the lipid/lysosomal or glycosylation
  branches to clinical manifestations because the retained literature does not
  establish those routes. The prior bundled neurologic/hepatic mechanism and
  its unsupported edge were removed. A separate, evidence-backed progressive
  cerebello-cerebral atrophy node now connects the primary VPS53/GARP lesion to
  the neurologic findings reported in the discovery cohort. Cerebellar atrophy
  (HP:0001272) replaces the earlier congenital cerebellar-hypoplasia assertion,
  matching the progressive PCCA observation. The disease is not
  parented as a type II congenital disorder of glycosylation: VPS53-knockout
  human cells show glycosylation defects, but direct patient glycosylation data
  are not present in the reviewed sources. Patient fibroblast and VPS53-knockout
  RPE1 models are now structured explicitly, and sphingolipid-synthesis
  inhibition is recorded only as a preclinical strategy. No diagnostic,
  differential-diagnosis, frequency, or established-treatment claims were
  added without source text that directly supports them.
📚

References & Deep Research

Deep Research

1
VPS53-Related Pontocerebellar Hypoplasia Type 2E Deep Research Fallback ▸

VPS53-Related Pontocerebellar Hypoplasia Type 2E Deep Research Fallback

Scope

No provider-generated deep research artifact was present on the WP-068 branch. This fallback audit documents the literature scope used to curate and review the VPS53-related entry from cached PubMed references.

Evidence Scope Used For Curation

  • PMID:24577744 for the VPS53/PCCA2 discovery report, autosomal recessive segregation, GARP-complex retrograde transport biology, patient fibroblast CD63-positive vesicular-body abnormalities, and the neurologic phenotype of profound developmental impairment, progressive microcephaly, spasticity, and early-onset epilepsy.
  • PMID:26357016 for GARP deficiency causing sphingolipid-intermediate accumulation, altered sterol distribution, lysosomal dysfunction, and sphingolipid abnormalities in PCCA2 patient fibroblasts.
  • PMID:34161137 for the broader GARP-dependent Golgi N- and O-glycosylation defect, including VPS53 knockout effects in human cells.
  • PMID:39842660 for a later VPS53-related PCH2E case with classic neurologic features plus liver disease and deafness.

Curation Conclusions

The supported model is biallelic VPS53 dysfunction causing GARP-complex retrograde-trafficking failure, abnormal endosomal vesicular bodies, downstream sphingolipid/lysosomal disruption, and Golgi glycoprotein-processing defects. The phenotype set should cover progressive microcephaly, epilepsy, pontocerebellar/cerebello-cerebral involvement, severe neurodevelopmental impairment, spasticity, and the reported hepatic and hearing extension features.